Victor Salloum, MD
Pulmonary Disease · Wichita, KSNPI 1598715682
Payments from drug & device makers
What this record shows
This record is dominated by education: $9,112 of the $14,177 with a category attached, or 64.3%. Intuitive Surgical accounts for 72.8% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2023 at $10,969 and has fallen 91.3% since, to $950 in 2025.
Across 207 payments — averaging $68.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$10K
- AstraZeneca$873
- GSK$797
- Sanofi$404
- Actelion Pharmaceuticals US, Inc.$283
- Boehringer Ingelheim$189
- plus $1K from 26 others
What the payments were for
- Travel & lodging$1,1018%
- Food & beverage$3,96528%
- Education$9,11264%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $10,315 |
| AstraZeneca | 40 | $873 |
| GSK | 59 | $797 |
| Sanofi | 16 | $404 |
| Actelion Pharmaceuticals US, Inc. | 7 | $283 |
| Boehringer Ingelheim | 10 | $189 |
| AbbVie(2 entities) | 6 | $157 |
| Veran Medical Technologies, Inc. | 3 | $149 |
| Grifols USA, LLC | 5 | $133 |
| Regeneron Healthcare Solutions, Inc. | 6 | $123 |
| Electromed, Inc. | 7 | $114 |
| Merck | 5 | $91 |
| Jazz Pharmaceuticals Inc. | 5 | $83 |
| Apria Healthcare LLC | 2 | $44 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Genentech USA, Inc. | 2 | $38 |
| Resmed Corp | 2 | $37 |
| United Therapeutics Corporation | 2 | $35 |
| Amgen | 2 | $33 |
| 3b Medical, Inc. | 2 | $25 |
| Johnson & Johnson | 1 | $22 |
| Viatris Specialty LLC | 1 | $20 |
| Gilead | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Vapotherm Inc | 1 | $18 |
| Hospira, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Harmony Biosciences LLC | 1 | $17 |
| Insmed, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,177 in reported general payments places this provider in the 85th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 512 | $383,074 |
| OfevNintedanib Esylate | 18 | $225,542 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 273 | $214,717 |
| Ambrisentan | 37 | $102,661 |
| Breo ElliptaFluticasone/Vilanterol | 255 | $101,725 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 185 | $90,897 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 142 | $80,275 |
| XolairOmalizumab | 23 | $74,185 |
| Spiriva RespimatTiotropium Bromide | 79 | $45,938 |
| Advair HfaFluticasone Propion/Salmeterol | 116 | $38,316 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 47 | $22,832 |
| SymbicortBudesonide/Formoterol Fumarate | 81 | $22,174 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 179 | $21,427 |
| Tadalafil | 20 | $18,723 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 120 | $17,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $797 | $587,185985 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $189 | $374,588286 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $873 | $236,891354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Wichita
- Abdel-Ghanie Abu-SamraWichita$60K
- Ibrahim RaphaelWichita$13K
- Nader EldikaWichita$9K
- Dennis Oyieng'oWichita$9K
- Mark WencelWichita$9K
- John FlesherWichita$7K
- Youssef YammineWichita$6K
- Raid Abu-AwwadWichita$6K
- Maged El-ZeinWichita$4K
- Son TruongWichita$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.